Key Points
- CEO Grigorios Siokas bought 388,532 shares on Feb 12 at an average price of $0.37, increasing his holdings to 8,861,914 shares (a 4.59% bump) in a $143,756.84 transaction.
- Siokas has made a string of insider purchases since mid‑December (multiple sizeable buys in January and February), signaling significant insider accumulation over recent weeks.
- Cosmos Health trades around $0.38 with a market cap of about $14.35M, reports negative earnings (missed last quarter and analysts expect about -0.78 EPS for the year), and carries an average analyst sentiment of "Sell" (Weiss Ratings: sell (d-)).
Cosmos Health Inc. (NASDAQ:COSM - Get Free Report) CEO Grigorios Siokas bought 388,532 shares of the business's stock in a transaction dated Thursday, February 12th. The stock was bought at an average cost of $0.37 per share, for a total transaction of $143,756.84. Following the completion of the purchase, the chief executive officer owned 8,861,914 shares of the company's stock, valued at approximately $3,278,908.18. The trade was a 4.59% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.
Grigorios Siokas also recently made the following trade(s):
- On Wednesday, February 11th, Grigorios Siokas purchased 291,262 shares of Cosmos Health stock. The stock was purchased at an average price of $0.41 per share, for a total transaction of $119,417.42.
- On Friday, January 23rd, Grigorios Siokas acquired 90,325 shares of Cosmos Health stock. The shares were purchased at an average price of $0.50 per share, with a total value of $45,162.50.
- On Tuesday, January 20th, Grigorios Siokas bought 353,321 shares of Cosmos Health stock. The stock was purchased at an average cost of $0.50 per share, with a total value of $176,660.50.
- On Wednesday, January 14th, Grigorios Siokas bought 493,495 shares of Cosmos Health stock. The stock was purchased at an average price of $0.45 per share, for a total transaction of $222,072.75.
- On Monday, January 12th, Grigorios Siokas purchased 113,185 shares of Cosmos Health stock. The shares were purchased at an average price of $0.50 per share, for a total transaction of $56,592.50.
- On Thursday, January 8th, Grigorios Siokas purchased 156,190 shares of Cosmos Health stock. The shares were purchased at an average cost of $0.52 per share, with a total value of $81,218.80.
- On Wednesday, January 7th, Grigorios Siokas acquired 124,880 shares of Cosmos Health stock. The stock was purchased at an average price of $0.52 per share, with a total value of $64,937.60.
- On Tuesday, January 6th, Grigorios Siokas acquired 133,953 shares of Cosmos Health stock. The stock was acquired at an average cost of $0.54 per share, for a total transaction of $72,334.62.
- On Friday, December 19th, Grigorios Siokas bought 88,314 shares of Cosmos Health stock. The shares were acquired at an average price of $0.49 per share, for a total transaction of $43,273.86.
- On Monday, December 15th, Grigorios Siokas purchased 168,472 shares of Cosmos Health stock. The stock was acquired at an average price of $0.42 per share, with a total value of $70,758.24.
Cosmos Health Trading Up 2.7%
Shares of NASDAQ:COSM opened at $0.38 on Friday. Cosmos Health Inc. has a 1 year low of $0.28 and a 1 year high of $1.32. The stock's fifty day moving average price is $0.48 and its 200-day moving average price is $0.73. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.99 and a quick ratio of 0.84. The company has a market cap of $14.35 million, a P/E ratio of -0.51 and a beta of 5.36.
Cosmos Health (NASDAQ:COSM - Get Free Report) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.16). Cosmos Health had a negative net margin of 31.01% and a negative return on equity of 33.19%. The company had revenue of $17.11 million for the quarter, compared to analysts' expectations of $16.40 million. Sell-side analysts expect that Cosmos Health Inc. will post -0.78 earnings per share for the current year.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Cosmos Health in a research note on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of "Sell".
Check Out Our Latest Stock Report on Cosmos Health
Hedge Funds Weigh In On Cosmos Health
An institutional investor recently raised its position in Cosmos Health stock. Renaissance Technologies LLC raised its stake in shares of Cosmos Health Inc. (NASDAQ:COSM - Free Report) by 260.5% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 334,575 shares of the company's stock after purchasing an additional 241,775 shares during the period. Renaissance Technologies LLC owned 0.89% of Cosmos Health worth $167,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 12.61% of the company's stock.
About Cosmos Health
(
Get Free Report)
Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
